1. Lilly says its monoclonal antibody prevented COVID-19 infections in trial — Roche gets priority review on blockbuster IPF drug — California says batch of Moderna vaccine is safe, despite reports of illnesses — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Latest News - ADU won't be approved

Discussion in 'BiogenIdec' started by anonymous, Oct 19, 2020 at 9:26 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    If Biogen decides to run another trial and there is adequate drug supply that might be an option.
     

  2. anonymous

    anonymous Guest

    They were right all along. Never be too pompous or over-confident in this industry. Odds are the FDA will not approve this drug. They will request an additional study.
     
  3. anonymous

    anonymous Guest

    you are dumb
     
  4. anonymous

    anonymous Guest

    Another phase 3 for sure. Will be a sign if wave 2 offers don’t go out
     
  5. anonymous

    anonymous Guest

    U be fucked.
     
  6. anonymous

    anonymous Guest

    Hold on everyone...they’re recounting the votes from today’s meeting!
     
  7. anonymous

    anonymous Guest

    Not funny. Everyone get your resumes updated!
     
  8. anonymous

    anonymous Guest

    lick my taint!
     
  9. anonymous

    anonymous Guest

    What do you think they will do regarding the upcoming offers? Do you think they will pull back on the offers given the votes today? It seems a little brash to continue to hire reps given the situation
     
  10. anonymous

    anonymous Guest

    You may be the dumbest one in this chat. Nah you’re ok. You’ll be hired.
     
  11. anonymous

    anonymous Guest

    They're going to pull out quicker than a musician with a groupie
     
  12. anonymous

    anonymous Guest

    Unfortunate news. I was sincerely hoping that the drug worked to help patients who desperately need something. But frankly, not a surprise at all. What is amazing to me is the press release a couple of days ago stating that scientists at the FDA were supportive. Of course the stock skyrocketed. Fast forward to today and the AD Board did exactly what most thought it would do. So the stock will drop on Monday when the market opens yet two days ago it skyrocketed. Talking about manipulating the market. Good luck to all who work there
     
  13. anonymous

    anonymous Guest

    100% agree
     
  14. anonymous

    anonymous Guest

    The drug will be approved.

    Today's vote was non-binding. The drug will be approved and doctors will be able to decide if they want to prescribe it or not.

    Remdesivir was approved, so there is no reason to think this won't be.

    That panel was nasty to the fda. How heartless can you be to tell patients they need to wait 4 more years? I would never want one of those acerbic twits to be my physician.
     
  15. anonymous

    anonymous Guest

    You’re delusional.
     
  16. anonymous

    anonymous Guest

    And your brain is clogged with butt paste.
     
  17. anonymous

    anonymous Guest

    Geeez...wake up! So they had a small amount of patients there that said they saw some benefit...think about a significantly larger patient pool that saw absolutely no benefit and worse, terrible side effects.
     
  18. anonymous

    anonymous Guest

    Agree with you here. Look to see who sold their stock after it jumped up last week.
     
  19. anonymous

    anonymous Guest


    This from Biogen's own site. The adcom recommends against approval:

    https://investors.biogen.com/news-r...sory-committees-meeting-aducanumab-alzheimers
     
  20. anonymous

    anonymous Guest

    So you want your physician to prescribe you something with the known side effect of brain edema, but that has not been proven to be effective? You sound like a Trumper ranting about hydroxychloroquine.